Guerbet's Vectorio Receives Registration in Taiwan

Guerbet (GBT), a global specialist in medical imaging, announces that the Ministry of Health & Welfare delivered registration for its innovative system for interventional oncology, Vectorio^®, in Taiwan.

Vectorio^® is a set of Lipiodol^® Ultra Fluid resistant medical devices ⁽¹⁾ including patented syringes, stopcock and sampling devices.

Vectorio^® is dedicated for mixing and delivering Lipiodol^® Ultra Fluid & anticancer drugs during cTACE procedure in adults with known, intermediate-stage hepatocellular carcinoma (HCC).

HCC is the most common primary liver cancer and is the fourth biggest cause of death due to cancer worldwide ⁽²⁾.

This medical device offers multiple advantages for healthcare professionals:

• 24 hours Lipiodol^® Ultra Fluid resistance ⁽¹⁾ - Reduce risks of leakage.
• Patented 3-way stopcock with 4 connections offering possibility of "On-table mixing" (interventional radiologists have the possibility of remixing without disconnection from the micro-catheter, thus maximizing the safety during the intervention).
• Ready-to-use set: all devices in one set.
• User-friendly: Ergonomic and quick device set-up, improving cTACE procedures for physicians.

Designed and manufactured in France, Vectorio^® 's commercial launch started in September 2017 in European countries. Today, Vectorio^® is registered in 25 countries over the world: two countries where Vectorio^® is registered for HCC imaging procedures, Canada & Germany; and 23 countries where Vectorio^® is registered for cTACE procedures ⁽³⁾.

References

1. Test report (E17-41) - Verification report of the device's functionality after 24h exposure to Lipiodol.
2. WHO - Globocan 2018 (IARC) Global Cancer Observatory.
3. Countries in which Vectorio^®is registered for cTACE: EMEA (Austria, Belgium, Czech Republic, Denmark, France, Hungary, Ireland, Luxembourg, Portugal, Switzerland, The Netherlands, Turkey), Americas (Argentina, Brazil, Mexico, Peru), Asia-Pacific (Hong Kong, India, New Zealand, South Korea, Taiwan, Thailand, Vietnam). Vectorio^® is also registered for HCC imaging in Germany & Canada.
4. Countries in which cTACE indication is registered for Lipiodol^®Ultra Fluid: EMEA (Austria, Belgium, Czech Republic, Denmark, France, Hungary, Iran, Ireland, Luxembourg, Portugal, Switzerland, The Netherlands, Tunisia, Turkey), Americas (Argentina, Colombia, Brazil, Chile, Mexico, Peru), Asia-Pacific (Brunei Darussalam, Cambodia, Hong Kong, India, Mongolia, New Zealand, Philippines, South Korea, Sri Lanka, Taiwan, Thailand, Vietnam). Countries in which HCC imaging indication is registered for Lipiodol^® Ultra Fluid: Canada, Germany, United States of America.
5. De Baere T. et al., Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion, Cardiovasc Intervent Radiol,2016;39: 334-343.